Nimodipine group — Competitive Intelligence Brief

Nimodipine group (Nimodipine group) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dihydropyridine calcium channel blocker. Area: Neurology / Cardiovascular.

phase 3 Dihydropyridine calcium channel blocker L-type voltage-gated calcium channel Neurology / Cardiovascular Small molecule

Target snapshot

Nimodipine group (Nimodipine group) — University Hospital Hradec Kralove. Nimodipine is a dihydropyridine calcium channel blocker that selectively inhibits L-type calcium channels in vascular smooth muscle, causing vasodilation and improved cerebral blood flow.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nimodipine group TARGET	Nimodipine group	University Hospital Hradec Kralove	phase 3	Dihydropyridine calcium channel blocker	L-type voltage-gated calcium channel
Amlodipine placebos	Amlodipine placebos	Shenzhen Ausa Pharmed Co.,Ltd	marketed	Calcium channel blocker (dihydropyridine)	L-type voltage-gated calcium channel
Olmesartan medoxomil ＋Azelnidipine	Olmesartan medoxomil ＋Azelnidipine	Jichi Medical University	marketed	Antihypertensive combination (ARB + calcium channel blocker)	Angiotensin II type 1 receptor (AT1R) and L-type voltage-gated calcium channels
Lercanidipine/enalapril fixed combination	Lercanidipine/enalapril fixed combination	Meir Medical Center	marketed	Calcium channel blocker / ACE inhibitor combination	L-type voltage-gated calcium channels; Angiotensin-converting enzyme (ACE)
Losartan/amlodipine or losartan/hydrochlorothiazide	Losartan/amlodipine or losartan/hydrochlorothiazide	Yokohama City University Medical Center	marketed	Angiotensin II receptor blocker combination (ARB + calcium channel blocker or ARB + thiazide diuretic)	Angiotensin II type 1 receptor (AT1R); L-type voltage-gated calcium channels (amlodipine) or sodium-chloride cotransporter (hydrochlorothiazide)
Losartan (+) amlodipine	Losartan (+) amlodipine	Organon and Co	marketed	Angiotensin II receptor blocker + calcium channel blocker combination	AT1 receptor (losartan); L-type voltage-gated calcium channel (amlodipine)
Amlodipine + Perindopril	Amlodipine + Perindopril	Centre for Chronic Disease Control, India	marketed	Calcium channel blocker + ACE inhibitor combination	L-type voltage-gated calcium channels; Angiotensin-converting enzyme (ACE)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dihydropyridine calcium channel blocker class)

1. Bayer · 1 drug in this class
2. CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · 1 drug in this class
3. Haseki Training and Research Hospital · 1 drug in this class
4. Jiangsu Simcere Pharmaceutical Co., Ltd. · 1 drug in this class
5. Korea University Guro Hospital · 1 drug in this class
6. Nanjing Yoko Biomedical Co., Ltd. · 1 drug in this class
7. Organon and Co · 1 drug in this class
8. Pfizer Inc. · 1 drug in this class
9. University Hospital Hradec Kralove · 1 drug in this class